Function Therapeutics is seeking to leverage a novel class of anti-inflammatory compounds, called parmodulins, for the treatment of diseases including sepsis/COVID-19, kidney disease, and osteoporosis. It is also working towards the development of oral analgesics for the treatment of inflammatory pain without significant addiction potential.